OSA LAAA MERGER CORP

ProSomnus Announces Third Quarter 2023 Investor Call and Business Update

ProSomnus Announces Third Quarter 2023 Investor Call and Business Update

PLEASANTON, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: ), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its third quarter financial results after market close on Thursday, November 9, 2023. ProSomnus Chief Executive Officer, Len Liptak, and Chief Financial Officer, Brian Dow, will host a conference call at 1:30 pm PT / 4:30 pm ET.

Investor Call Dial-In Information

Interested parties may register for the conference call using the following link: . You may access the live webcast of the conference call by using the following link: . The link will also be posted in the Investor Relations section of the ProSomnus website at .

About ProSomnus

ProSomnus (NASDAQ: ) is a leading CPAP alternative for the treatment of Obstructive Sleep Apnea, a serious medical disease affecting over 1 billion people worldwide, that is associated with comorbidities including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. Non-invasive, patient preferred and easy to use, ProSomnus devices have demonstrated excellent efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. ProSomnus precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government sponsored healthcare plans around the world, representing over 200 million covered lives. To learn more, visit .

Investor Contact

Mike Cavanaugh

ICR Westwicke

Phone: +1.617.877.9641

Email: 

Media Contact

Elizabeth Coleman

ICR Westwicke

Phone: +1.203.682.4783

Email: 

 



EN
31/10/2023

Underlying

OSALAAA MERGER CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LAAA MERGER CORP

 PRESS RELEASE
Free
OSA LAAA MERGER COR...

ProSomnus® Sleep Technologies Announces Record Revenues as it Emerges ...

ProSomnus® Sleep Technologies Announces Record Revenues as it Emerges from Reorganization PLEASANTON, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProSomnus Sleep Technologies (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced record revenues for the quarter ended June 30, 2024 as it formally emerges from reorganization on August 5, 2024. Revenues for the second quarter totaled a record $9.1 million reflecting increasing orders for the Company’s precision intraoral medical devices. These quarterly results reflect a 22% increase over the first quarter of ...

August 7, 2024 1 EN
 PRESS RELEASE
Free
OSA LAAA MERGER COR...

ProSomnus Contributes Two Scientific Abstracts for Presentation at SLE...

ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024, A Joint Meeting of the American Academy of Sleep Medicine and the Sleep Research Society PLEASANTON, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that it has contributed two scientific abstracts that have been accepted for presentation at , a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, June 1-5 in Houston, TX. Abstract ID 1262“Evaluating the Clinical Performance of a N...

May 30, 2024 1 EN
 PRESS RELEASE
Free
OSA LAAA MERGER COR...

ProSomnus Announces Strong First Quarter 2024 Revenue Growth

ProSomnus Announces Strong First Quarter 2024 Revenue Growth ProSomnus Records 28% Year-Over-Year Revenue Growth Accompanied by Continued Strong Customer Satisfaction PLEASANTON, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy, today announced results for the first quarter ended March 31, 2024. Revenue for the first quarter of 2024 totaled $7.5 million, an increase of $1.7 million or 28% compared to $5.8 million for the first quarter of 2023 representing one of the highest growth rates in sleep medicin...

May 16, 2024 1 EN
 PRESS RELEASE
Free
OSA LAAA MERGER COR...

ProSomnus Contributes Two Scientific Abstracts Accepted for Presentati...

ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting PLEASANTON, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that it has contributed two scientific abstracts that have been accepted for presentation at the 2024 American Academy of Dental Sleep Medicine Meeting in New Orleans. Abstract #019“Assessing Health Outcomes When Treating Obstructive Sleep Apnea with Mandibular Protruding Appliances”Erin ...

May 13, 2024 1 EN
 PRESS RELEASE
Free
OSA LAAA MERGER COR...

Four Independent Scientific Abstracts at the American Academy of Denta...

Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices PLEASANTON, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that four independent scientific abstracts accepted for the 2024 AADSM Annual Meeting contain scientific data utilizing ProSomnus precision devices, with one abstract winning the prestigious Clinical Excellence Award, and another featuring over 1,200 patients. Abstract #018 (Winner of t...

May 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch